Investigation of response of patients with non‐small cell lung cancer to docetaxel (plus ramucirumab) therapy in second‐line treatment

Abstract

AbstractBackgroundSeveral options for second‐line therapy are available for patients with advanced non‐small cell lung cancer (NSCLC); however, the optimal therapy remains unclear. Docetaxel (DTX) monotherapy and DTX plus ramucirumab (RAM) are the recommended second‐line treatment options. However, the efficacy of these treatments remains unsatisfactory. The aim of this study was to identify the clinical characteristics of patients with NSCLC who respond to DTX or DTX + RAM and factors that predict response.MethodsPatients with NSCLC treated with DTX or DTX + RAM after second‐line therapy were retrospectively analyzed. Patients were compared with those who responded or did not respond to the post‐treatment efficacy assessment.ResultsOf 53 patients, 12 (22.6%) had lung cancer that responded to DTX or DTX + RAM therapy (response group). Multivariate analysis identified the absence of immune checkpoint inhibitors (ICIs) in the immediate prior therapy and a reduced dose of DTX after the second cycle as significant independent risk factors predicting nonresponse to DTX and DTX + RAM therapy in patients with NSCLC. The overall survival was significantly longer in the response group compared to the nonresponse group (p = 0.016).ConclusionsOur results suggest that DTX and DTX + RAM therapies immediately after treatment with ICI‐containing regimens as well as continuation of DTX without dose reduction after the second cycle may increase the response rate and prolong survival in patients with NSCLC.